suPAR in cardiovascular disease

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Biomarker Discovery

Background:

• Soluble urokinase plasminogen activator receptor (suPAR) is the circulating form of cell surface uPAR.
• suPAR shares structural and functional similarities with its parent molecule, involved in fibrinolysis, cell adhesion, and migration.
• suPAR is increasingly recognized for its association with inflammatory processes.

Purpose of the Study:

• To review the current understanding of suPAR in cardiovascular disease (CVD).
• To explore the potential of suPAR as a biomarker for inflammatory activation in CVD.
• To assess suPAR's role in risk stratification and clinical utilization for CVD.

Main Methods:

• Literature review of studies investigating suPAR in various cardiovascular conditions.
• Analysis of data correlating suPAR levels with disease progression and patient outcomes.
• Examination of suPAR's association with traditional cardiovascular risk factors.

Main Results:

• Increased suPAR levels independently predict adverse outcomes in acute coronary syndromes, heart failure, coronary artery disease, and atherosclerosis.
• suPAR has been evaluated for improved risk discrimination in numerous CVD settings.
• Emerging evidence suggests a mechanistic involvement of suPAR in cardiovascular disease pathogenesis.

Conclusions:

• suPAR shows significant potential as a predictive biomarker in cardiovascular diseases.
• Further research is needed to elucidate the mechanistic role of suPAR in CVD.
• suPAR may aid in refining clinical risk assessment and guiding therapeutic strategies for CVD patients.